Pfizer, Novartis, Merck, and Intravacc are competing in the high-cost gene therapy market, utilizing specialized manufacturing and vaccine production services.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer, Novartis, Merck, and Intravacc are competing in the high-cost gene therapy market, utilizing specialized manufacturing and vaccine production services.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.Also in this story
- Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.
- Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Merck
public company in Indonesia
Related events
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Major pharmaceutical companies are competing for investment capital.
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- BioNTech announced new partnerships with Genmab, Pfizer, Bristol-Myers Squibb, and Genentech.